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IMPORTANCE Glioblastoma is an incurable tumor, and the therapeutic options for patients are
limited.
OBJECTIVE To determine whether the systemic administration of HER2-specific chimeric
antigen receptor (CAR)–modified virus-specific T cells (VSTs) is safe and whether these cells
have antiglioblastoma activity.
DESIGN, SETTING, AND PARTICIPANTS In this open-label phase 1 dose-escalation study
conducted at Baylor College of Medicine, HoustonMethodist Hospital, and Texas Children’s
Hospital, patients with progressive HER2-positive glioblastomawere enrolled between July
25, 2011, and April 21, 2014. The duration of follow-up was 10 weeks to 29months (median, 8
months).
INTERVENTIONS Monotherapy with autologous VSTs specific for cytomegalovirus,
Epstein-Barr virus, or adenovirus and genetically modified to express HER2-CARs with a
CD28.ζ-signaling endodomain (HER2-CAR VSTs).
MAIN OUTCOMES ANDMEASURES Primary end points were feasibility and safety. The key
secondary end points were T-cell persistence and their antiglioblastoma activity.
RESULTS A total of 17 patients (8 females and 9males; 10 patients18 years [median age, 60
years; range, 30-69 years] and 7 patients <18 years [median age, 14 years; range, 10-17 years])
with progressive HER2-positive glioblastoma received 1 or more infusions of autologous
HER2-CAR VSTs (1 × 106/m2 to 1 × 108/m2) without prior lymphodepletion. Infusions were
well tolerated, with no dose-limiting toxic effects. HER2-CAR VSTs were detected in the
peripheral blood for up to 12 months after the infusion by quantitative real-time polymerase
chain reaction. Of 16 evaluable patients (9 adults and 7 children), 1 had a partial response for
more than 9months, 7 had stable disease for 8 weeks to 29months, and 8 progressed after
T-cell infusion. Three patients with stable disease are alive without any evidence of
progression during 24 to 29months of follow-up. For the entire study cohort, median overall
survival was 11.1 months (95% CI, 4.1-27.2 months) from the first T-cell infusion and 24.5
months (95% CI, 17.2-34.6months) from diagnosis.
CONCLUSIONS AND RELEVANCE Infusion of autologous HER2-CAR VSTs is safe and can be
associated with clinical benefit for patients with progressive glioblastoma. Further evaluation
of HER2-CAR VSTs in a phase 2b study is warranted as a single agent or in combination with
other immunomodulatory approaches for glioblastoma.
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G lioblastoma is themost aggressive primary brain can-cer. Despitemultimodal therapy that combinesmaxi-mal surgical resection with postoperative adjuvant
chemoradiotherapy, 5-year overall survival (OS) rates have re-
mained less than4%foradultsand less than16%forchildren.1,2
Tumor-targeted immunotherapy has the potential to im-
prove outcomes because it does not rely on the cytotoxic
mechanisms of conventional therapies to which glioblas-
toma cells are resistant. Results from completed early-phase
clinical trials with peptide, tumor cell, or dendritic cell vac-
cines for patients with glioblastoma have been encouraging,
demonstrating clinical benefit.3-6
Cellular immunotherapy with adoptively transferred
chimeric antigen receptor (CAR)–modified T cells is an at-
tractive option to improve the outcomes for patients with
glioblastoma.6,7 Chimeric antigen receptors usually recog-
nize unprocessed antigens expressed on the surface of can-
cer cells. For glioblastoma-directed CAR T-cell therapy, sev-
eral cell surface proteins are actively targeted in preclinical
models, including interleukin 13Rα2 (IL-13Rα2), EphA2,
EGFRvIII, and HER2.8-12 For example, Ahmed et al11 have
shown thatHER2-CARTcells kill both “bulk” gliomacells and
glioma-initiating cells and have potent antitumor activity in
preclinical xenograft models derived from patients with
glioblastoma.
Despite the potential benefit of HER2-CAR T cells, safety
concerns were raised by the death of 1 patient, who received
1 × 1010 T cells expressing a third-generationHER2-CARwith a
trastuzumab-based antigen recognition exodomain and a
CD28.41BB.ζ signaling endodomain, and IL-2 after lymphode-
pleting chemotherapy.13 We therefore developed a second-
generation HER2-CAR with an FRP5-based exodomain and a
CD28.ζ endodomain.An initial safety evaluationofHER2-CAR
T cells (up to 1 × 108/m2) in patients with sarcoma demon-
strated no evident toxic effects and some indicators of antitu-
mor activity; however, T-cell persistence was limited.14
Onepotential strategy tooptimize thepersistenceof adop-
tively transferred T cells relies on the expression of CARs in
virus-specific T cells (VSTs).15 These cells not onlyprovide an-
titumor activity through their CAR but may also receive ap-
propriate costimulation following native T-cell receptor
(αβTCR)engagementby latentvirusantigenspresentedbypro-
fessional antigen-presenting cells. Our center has established
the safety of adoptively transferred polyclonal VST lines, en-
riched for cytomegalovirus (CMV), Epstein-Barr virus (EBV),
and adenovirus (Adv), in hematopoietic stem cell transplant
recipients.16,17 We thus developed a phase 1 dose-escalation
studyof infusingHER2-CAR–modifiedautologousVSTs (HER2-
CAR VSTs) in patients with progressive glioblastoma and,
herein, report on their safety, persistence, and antitumor
activity.
Methods
Study Design and Participants
This open-label phase 1 clinical trialwas approved by the pro-
tocol review committee of the Dan L. Duncan Comprehen-
sive Cancer Center at Baylor College of Medicine, the institu-
tional biosafety committee and the institutional review board
ofBaylor College ofMedicine, theRecombinantDNAAdvisory
Committeeof theNational InstitutesofHealth,andtheUSFood
and Drug Administration (NCT01109095). All procedures
involving human participants were carried out in accordance
to theDeclarationofHelsinki.18Written informed consentwas
obtained from patients or guardians before enrollment in the
study. This trial used the modified continual assessment
method,witha cohort sizeof 3patientsperdose level. Patients
received 1 or more intravenous infusions of autologous
HER2-CARVST at 5 dose levels (1 × 106/m2, 3 × 106/m2, 1 × 107
/m2, 3 × 107/m2, and 1 × 108/m2). Patientswhohadanobjective
response at 6 weeks or at subsequent evaluation were eligible
to receive up to 6 additional doses of T cells at 6- to 12-week
intervals at the samedose level.All patients received infusions
betweenJuly25,2011,andApril21,2014.Themedianfollow-up
period was 8months (range, 10 weeks to 29months).
Patients with histologically proven progressive recurrent
glioblastoma(WorldHealthOrganizationgrade IVglioma)were
enrolled in the study after the diagnosis was confirmed by 2
independent pathologists (J.H. and S.Z.P.) (Figure 1). All pa-
tients underwent magnetic resonance imaging (MRI) to as-
sess their disease before T-cell infusion. Eligibility criteria in-
cludedHER2-positiveglioblastoma,CMVseropositivity,normal
left ventricular ejection fraction, Karnofsky/Lansky perfor-
mance score of 50 ormore, and life expectancy of 6 weeks or
more at the time of T-cell infusion. Patients had to have com-
pleted (and recovered from) cytotoxic therapyat least 4weeks
beforeT-cell infusion.Oneexceptionwastemozolomide(TMZ);
owing to its extremely short half-life, patients were allowed
to receive TMZ up to 2 days prior to T-cell infusion. Exclusion
criteria included human immunodeficiency virus seroposi-
tivity, inadequate liver function, and renal insufficiency.
Procedures
AutologousHER2-CARVSTproductsweremanufactured from
up to 90 mL of peripheral blood according to current Good
ManufacturingPracticeguidelines,aspreviouslydescribed,16,17
and are outlined indetail in the eAppendix in the Supplement.
Key Points
Question What is the safety and antitumor efficacy of autologous
HER2-specific chimeric antigen receptor (CAR)–modified
virus-specific T cells (VSTs) in patients with progressive
glioblastoma?
Findings This phase 1 dose-escalation study established the
safety of autologous HER2-CAR VSTs in 17 patients with
progressive glioblastomawith no serious adverse events. Eight
patients had a clinical benefit, with a median overall survival of 11.1
months after T-cell infusion and 24.5 months after diagnosis, and 3
patients were alive with no disease progression at the last
follow-up.
Meaning Infusion of autologous HER2-CAR VSTs is safe, with
some indication of clinical benefit, and evaluation in a phase 2b
study is warranted.
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The clinical grade retroviral vector used for transduction en-
codedasecond-generationHER2-CAR(FRP5.CD28.ζ).14HER2-
CAR VSTs were tested for sterility, HLA identity, immunophe-
notype, and specificity for HER2 and virus (Adv, CMV, or EBV)
at the time of cryopreservation.
Toxic effects were monitored using the National Cancer
Institute Common Terminology Criteria for Adverse Events,
version 4.X.19 Peripheral blood samples were obtained prior
to T-cell infusions and then at regular predetermined time
points to evaluate for infusion-related toxic effects and toper-
form correlative studies (quantitative real-time polymerase
chain reaction [qPCR] and enzyme-linked immunospot
[Elispot] assays [eAppendix in the Supplement]).
Clinical Response Criteria
Clinical response toT-cell infusionwas evaluatedbyperform-
ingMRI prior to and 6weeks after T-cell infusion. Disease re-
sponsewasdefined as a complete response (disappearance of
all initial markers of disease), a partial response (30% de-
crease in the longest diameter of the tumor), a progressivedis-
ease (20% increase in themeasurement of tumor), or a stable
disease (small changes that donotmeet the criteria for partial
response or progressive disease). Patients with evidence of
clinical benefit (complete response, stable disease, or partial
response) at the6-weekevaluationwere eligible to receive ad-
ditional doses of T cells.
Outcomes
The primary objective of this study was to define the maxi-
mumtolerateddose and safetyof autologousHER2-CARVSTs
inpatientswithglioblastoma.Secondaryobjectiveswere tode-
termine the in vivo fate of infused T cells and their antiglio-
blastoma activity.
Statistical Analysis
Safety data were described by the number and proportion of
patientswhohad treatment-related toxic effects. Progression-
free survival andOSwere analyzedusingKaplan-Meiermeth-
ods. Transgene expression and Elispot assays were summa-
rized over time using descriptive statistics. The significance
between groups was determined by use of the 2-tailed t test
or the Fisher exact test. P < .05 was considered statistically
significant. Univariate Cox proportional hazards regression
analysiswas used to analyze the associations of potential risk
factors with response and survival outcomes.
Results
Patient Characteristics
Between July 25, 2011, and April 21, 2014, 17 patients (8 fe-
males and 9 males) with recurrent or progressive glioblas-
tomawere enrolled in the study (eTables 1 and2 in theSupple-
ment).Tenof 17patientswere 18yearsorolder (medianage,60
years; range, 30-69 years). Seven patients were younger than
18 years of age (median age, 14 years; range, 10-17 years). Six-
teenpatientswere seropositive forCMV,andall 17patientshad
a HER2-positive glioblastoma (eFigure 1 in the Supplement).
Sixteen patients had surgical resections followed by radio-
therapywith concomitantTMZ.Eight of 17 patients (47%)had
undergone2ormore surgical resections.All adult patients and
3of7pediatricpatientshadreceivedTMZfor6monthsormore.
Ten patients (59%) had failed 1 to 5 lines of additional salvage
therapies, and 6 patients (35%) had received investigational
therapies prior to studyenrollment.Onepatient (patient 5) re-
ceived TMZ until 2 days prior to T-cell infusion, while 16 pa-
tients had not received chemotherapeutic or investigational
agents for at least 4 weeks. The median time to T-cell infu-
sion fromdiagnosiswas 12.9months (range, 5.9-27.2months).
All enrolled patients hadnormal absolute lymphocyte counts
(mean, 1130/μL; range, 421-2318/μL [to convert to ×109 per li-
ter, multiply by 0.001]) at the time of T-cell infusion.
Characteristics of Clinical Grade HER2-CAR VSTs
The mean HER2-CAR transduction efficiency of HER2-CAR
VSTs was 39% (range, 18%-67%; eFigure 2A in the Supple-
ment). Cell products containedCD3+/CD8+ (mean, 71%; range,
16%-97%) and CD3+/CD4+ (mean, 24%; range, 0.3%-88%) T
cells. Most T cells had a memory phenotype consisting of ef-
fector and central memory T-cell subsets (eFigure 2B in the
Supplement). In standard assays for cytotoxic effects, HER2-
CAR VSTs had significant cytotoxic effects against the
HER2-positive glioma cell line U373, in contrast to unmodi-
fiedVSTs.OnlybackgroundkillingwasobservedagainstHER2-
negativeK562 (eFigure2C in theSupplement).HER2-CARVSTs
of all patients with a glioblastoma contained Adv- and EBV-
specific T cells; in addition, all HER2-CAR VSTs from CMV-
seropositive patients contained CMVpp65-specific T cells as
judgedby interferongamma(IFN-γ)Elispot assays (eFigure2D
in the Supplement).
Safety and In Vivo Detection of HER2-CAR VSTs
Seventeen patients received a total of 30 infusions, with 6
patients receivingmultiple infusions (eTable 3 in the Supple-
ment). No dose-limiting toxicity was observed; however,
Figure 1. CONSORT FlowDiagram
1 Excluded for receipt of
chemotherapy
17 Completed intervention and received T-cell product
17 Included in survival analysis
23 Assigned to receive T cells
41 Patients assessed for eligibility
18 Excluded
5 With clinical decline
1 Lost interest
12 With HER2-negative tumor
6 Excluded for clinical decline
16 Included in safety analysis
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patients 3and16hadgrade2seizuresand/orheadaches,which
wereprobably related to theT-cell infusion (Table). At6weeks
after the infusion, the results of cardiac function studies
showed that the left ventricular ejection fractions were un-
changed from their preinfusion values. HER2-CARVSTswere
detected by qPCR in all patients after the infusion. Fifteen of
17 patients had their highest frequency of HER2-CAR VSTs 3
hours after the infusion (mean, 7.8 copies/μgDNA; range, 1.4-
27.8 copies/μg DNA), 1 patient had the highest frequency of
HER2-CAR VSTs at 1 week after the infusion (2.0 copies/μg
DNA), and 1 patient had the highest frequency of HER2-CAR
VSTs at 2 weeks after the infusion (7.2 copies/μg DNA)
(eFigure 3A and 3B in the Supplement). At 6 weeks after the
infusion, HER2-CAR VSTs were present in 7 of 15 patients
(mean, 2.0 copies/μgDNA; range, 0.7-3.8). Sixweeks after in-
fusion, the frequency of qPCR-positive blood samples de-
clined,with 1 of 6 samples positive at 3months, 2 of 7 samples
positive at 6months, 2 of 3 samples positive at 9months, 2 of
6 samples positive at 12 months, and no samples positive at
18 or 24 months (eFigure 3B in the Supplement). These re-
sults indicate that HER2-CAR VSTs did not expand after the
infusion but could persist for 1 year at a low frequency. Infus-
ingmultiple doses of HER2-CAR VSTs did not change their in
vivo fate (eFigure 3C in the Supplement).
HER2-CARVST products contained T cells that were spe-
cific for CMV (pp65), Adv, andEBV ( eFigure 2D in the Supple-
ment). The IFN-γElispot assayswereused tomeasure the fre-
quency of these VSTs in the peripheral blood of patients who
received infusions. The precursor frequency of CMV (pp65)-,
Adv-, and EBV-specific T cells did not change in comparison
with an endogenous control (CMV IE1-specific T cells), con-
firming our qPCR result that infused HER2-CAR VSTs did not
expand (eFigure 4 in the Supplement).
Tumor Responses and Survival After HER2-CAR VST Infusion
To evaluate the antiglioblastoma activity of HER2-CARVSTs,
MRI of the brain was performed 6 weeks after T-cell infusion
(Figure 2A). Patient 14 received chemotherapywithin the first
6 weeks of T-cell infusion and was excluded from the re-
sponse analysis.Of 16 evaluablepatients, 1 (6%;patient 4) had
apartial response, and7 (44%)hada stabledisease for8weeks
to 29 months after the first T-cell infusion (eTable 3 in the
Supplement). Patient 4, a 17-year-old male with an unresect-
able right thalamic glioblastoma (maximum dimension, 4.6
cm), received HER2-CAR VSTs (1 × 106/m2) and had a partial
response that lasted for 9.2 months (Figure 2A). He then had
a stable disease after a second infusion at the same dose level
and survived for 26.9 months from the first infusion (eTable
3 in the Supplement). Three patients (18%; patients 8, 9, and
13) are alive with a stable disease for 29.0, 28.8, and 24.0
months of follow-up. Eight patients had aprogressive disease
based on Response Evaluation Criteria In Solid Tumors
criteria.20 Despite a progressive disease, 6 patients survived
for more than 6 months (range, 6.1-15.5 months; Figure 2B).
For theentire studycohort, themedian timetoprogressionwas
3.5 months; median OS was 11.1 months (95% CI, 4.1-27.2
months) after the first T-cell infusion and 24.5 months (95%
CI, 17.2-34.6months) after diagnosis.Weperformedanexten-
sive univariate Cox proportional hazards regression analysis
to evaluate if age at diagnosis, sex, grade or intensity of HER2
positivity, number of T-cell infusions, or phenotype of in-
fused T cells were associatedwith OS (eTable 4 in the Supple-
ment). We found no correlation except that patients who did
not receive salvage therapy prior to infusion had a signifi-
cantly longermedianOS (27.2months) than did patientswho
received infusion after salvage therapy (6.7 months; P = .02;
eTable 4 in the Supplement).
Discussion
In thisphase 1dose-escalation study,weestablished the safety
of autologousHER2-CARVSTs in 17 patientswith progressive
glioblastoma.AlthoughHER2-CARVSTsdidnot expand, they
were detectable in the peripheral blood for up to 12 months.
Eight patients had clinical benefit as defined by a partial re-
sponse (n = 1) and a stable disease (n = 7). ThemedianOSwas
11.1 months after T-cell infusion and 24.5 months after diag-
nosis.Threepatientswithastablediseasewerealiveat the time
of last follow-up with no disease progression.
Chimeric antigen receptor T-cell therapies are an attrac-
tive strategy to improve the outcomes for patients with glio-
blastoma. To our knowledge, only 1 study inwhich 3 patients
with glioblastoma receivedan intratumoral injectionofT cells
that were genetically modified with a first-generation
IL-13Rα2-specific CAR has been published.8 Local injections
were well tolerated, and 2 of the 3 patients had a transient
clinical response. In our study, we infused HER2-CAR VSTs
intravenously because T cells can travel to the brain after
intravenous injections, as evidenced by clinical responses af-
ter the infusion of tumor-infiltrating lymphocytes for mela-
noma brain metastasis21 and by detection of CD19-CAR T
cells in the cerebrospinal fluid of patients with B-precursor
leukemia.22
Infusion of HER2-CAR VSTs of up to 1 × 108/m2 was well
toleratedwithoutdose-limiting toxic effects.HER2-CARVSTs
did not expand but were present in the peripheral blood for
up to 1 year after infusion. Theobservationof noT-cell expan-
sion is in agreement with previous studies in which patients
withglioblastoma receivedunmodifiedCMV-specificTcells,23
patients with EBV-positive nasopharyngeal carcinoma re-
ceived EBV-specific T cells,24,25 or patients with neuroblas-
toma received EBV-specific T cells genetically modified to
expressGD2-CARs (GD2-CAR/EBVTcells).15 Lackof invivoex-
pansion of CMV cells, EBV T cells, and GD2-CAR/EBV T cells
in thesestudiescontrastswiththesignificantexpansionofVSTs
in hematopoietic stem cell transplant recipients, who are se-
verely lymphodepleted and have experienced reactivation of
the corresponding virus.16,26 Since patients with glioblas-
toma in our study had normal absolute lymphocyte counts at
the time of T-cell infusion, lymphodepleting chemotherapy
and/or the provision of viral antigens in the form of vaccines
arepotential strategies to increase their invivoexpansion.Lym-
phodepleting chemotherapyhas been shown to be critical for
the robust expansion of CD19-CART cells in patientswith he-
matologicmalignant neoplasms,22,27 and vaccines have been
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Table. Adverse EventsWithin the First 6Weeks After HER2-CAR VST Infusion
Adverse Event
No. (%) of Patients
(N = 17)
Grade 2 Grade 3 Grade 4
Probably related
Central nervous system 0 0 0
Headache 1 (6) 0 0
Seizure 2 (12) 0 0
Unrelated
Hematologic toxic effects
Anemia 1 (6) 0 0
Lymphopenia 7 (41) 2 (12) 0
Neutropenia 2 (12) 0 1 (6)
Thrombocytopenia 1 (6) 0 0
Nonhematologic toxic effects
General
Anorexia 1 (6) 0 0
Fatigue 0 1 (6) 0
Somnolence 1 (6) 0 0
Weakness 2 (12) 1 (6) 0
HEENT
Eye paralysis, lateral 1 (6) 0 0
Gastrointestinal
Nausea 2 (12) 0 0
Diarrhea 1 (6) 0 0
Constipation 1 (6) 0 0
Vomiting 2 (12) 0 0
Cardiac
Bradycardia 1 (6) 0 0
Respiratory
Atelectasis 1 (6) 0 0
Pain
Extremity 1 (6) 0 0
Bone 1 (6) 0 0
Myalgia 1 (6) 0 0
Musculoskeletal
Edema, localized 1 (6) 0 0
Fracture 1 (6) 0 0
Central nervous system
Headache 0 2 (2) 0
Seizure 1 (6) 0 0
Gait disturbance 2 (12) 0 0
Memory impairment 1 (6) 0 0
Tremors 1 (6) 0 0
Cerebral edema 0 0 1 (6)
Hydrocephalus 0 1 (6) 0
Infectious
Urinary tract infection 1 (6) 0 0
Laboratory test results
Elevated ALT 1 (6) 0 0
Elevated AST 1 (6) 0 0
Hyperbilirubinemia 1 (6) 0 0
Hyperkalemia 1 (6) 0 0
Hypernatremia 1 (6) 0 0
Hyponatremia 1 (6) 1 (6) 0
Abbreviations: ALT, alanine
aminotransferase; AST, aspartate
aminotransferase; HEENT, head, ears,
eyes, nose, and throat;
HER2-CAR VST, HER2–chimeric
antigen receptor virus-specific T cell.
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used successfully to boost the expansion of CAR VSTs in pre-
clinical models.28
Althoughwe did not observe an expansion of HER2-CAR
VSTs in the peripheral blood, T cells could have expanded at
glioblastoma sites. At 6 weeks after T-cell infusion, the MRI
scansof patients 3, 7, 10, 16, and 17 showedan increase inperi-
tumoral edema.Althoughthesepatientswereclassifiedashav-
ing a progressive disease, it is likely that the imaging changes
for some of these patients were due to inflammatory re-
sponses, indicative of local T-cell expansion, especially since
thesepatients survived formore than6months. Local inflam-
matory responses, so-calledpseudoprogression,havebeenob-
served in several immunotherapy studies, including those for
glioblastoma.3 In this regard, the Response Assessment for
Neuro-Oncology working group recently published their rec-
ommendation for immunotherapy studies.29
We infused T cells that could potentially recognize HER2
and pp65 expressed in glioblastoma. Five patients had a glio-
blastoma that was positive for pp65; 2 of these patients had a
progressive disease, and 3 had a stable disease. A larger co-
hort of patients with pp65-positive glioblastoma is needed to
determine if pp65 expression is associated with the antiglio-
blastomaactivity ofHER2-CARVSTs.Outcomesdata onpost-
progressionsurvivalofpatientswithglioblastomaare limited.30
One recent Italian study performed a retrospective outcomes
analysis of 232 patients with glioblastoma who received sec-
ond-line chemotherapy at disease progression after radio-
therapywithTMZ.30Themedianprogression-freesurvivalwas
2.5months, and themedianpostprogression survivalwas 8.6
months. A randomized controlled clinical phase 2 trial com-
pared the combination of bevacizumab plus lomustine with
single-agent bevacizumab or lomustine in patients with glio-
blastomawhose front-line therapy had failed.31 Although be-
vacizumab and lomustinewerewell tolerated, the lomustine
dose needed to be reduced in the bevacizumab plus lomus-
tine arm. Fifty-two patients who received bevacizumab plus
lomustine had the best outcome, with a median OS of 12
months and an 18-month OS of 20%. In our cohort, in which
second-line therapy failed for 10 of the 17 patientswith a glio-
blastoma, we achieved similar outcomes (median OS, 11.1
months; 18-month OS, 29.4%) with a median of 1 HER2-CAR
VST infusion (range, 1-6 infusions) without evident toxic ef-
fects. Limiting the analysis to the 7 patients who received in-
fusionswithouthavingreceivedsalvage therapyrevealedame-
dian OS of 27.2 months and an 18-month OS of 43%.
Limitations
No definitive conclusions regarding survival benefit based on
historical controls canbemade fromthe resultsofphase 1 clini-
cal studies like ours. In addition to the small sample size, we
also had attrition from screening patients for HER2 positivity
to T-cell infusion (Figure 1). However, of 23 clinical-grade
Figure 2. Clinical Outcome After HER2–Chimeric Antigen Receptor Virus-Specific
T-Cell (HER2-CAR VST) Infusions
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HER2-CAR VST products generated, 17 were infused, which is
within the25%to30%expected rateofattrition for cell therapy
studies at our center, and all patients who received infusions
were includedinthesurvivalanalysis. Inclusionofchildren(<18
years),whohaveabetterprognosis thanadults,mighthavealso
affected the outcome.2 However, there was no significant dif-
ference between the survival probability for children and that
for adults in this clinical study. Although the small sample size
most likely contributed to our finding, 4 of 8 pediatric patients
were also heavily pretreated, and 1 patient had no resection of
the primary tumor owing to its location.
There is a need to improve the antiglioblastoma activity
of HER2-CAR VSTs. Besides lymphodepletion and/or immu-
nization with a CMVpp65 vaccine to enhance the in vivo ex-
pansionandpersistenceofadoptively transferredTcells, other
manipulationsof the immunesystemmightbenecessary, such
asblocking inhibitorymolecules that are expressedon the cell
surface (eg, programmed cell death ligand 1 [PD-L1]) or se-
creted (eg, transforming growth factor β [TGF-β]) by glioma
cells.32,33 In this regard, itwouldhavebeen informative tohave
performed additional correlative studies to monitor the phe-
notype of lymphocytes and myeloid cells before and after T-
cell infusion. However, owing to sample availability, we re-
stricted our analysis to the discussed transgene qPCRs and
Elispot assays. In addition, performing studies (eg,CD107ade-
granulation or cytotoxicity assay) to determine the function-
ality ofHER2-CARVSTs after infusionwouldhave been infor-
mative, but these studies were not possible owing to the low
frequency of HER2-CAR VSTs. Finally, antigen expression in
glioblastoma is heterogeneous, and targeting multiple anti-
gensmayalsohave thepotential to improve response ratesand
outcomes.34,35
Conclusions
Treatment of progressive glioblastoma with HER2-CAR VSTs
is feasible and safe and resulted in clinical benefit for 8 of 17
patients.Although thesedata support larger studies, they also
highlight theneed to improve the antiglioblastomaactivity of
HER2-CARVSTsbyaugmenting their expansion, function, and
persistence.
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